Insight Wealth Strategies LLC Grows Stock Holdings in Cencora, Inc. (NYSE:COR)

Insight Wealth Strategies LLC increased its position in shares of Cencora, Inc. (NYSE:COR) by 124.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,249 shares of the company’s stock after acquiring an additional 11,232 shares during the period. Insight Wealth Strategies LLC’s holdings in Cencora were worth $4,549,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Iowa State Bank increased its stake in Cencora by 3.2% during the 4th quarter. Iowa State Bank now owns 6,375 shares of the company’s stock worth $1,432,000 after buying an additional 198 shares during the period. CWA Asset Management Group LLC increased its position in shares of Cencora by 23.6% during the fourth quarter. CWA Asset Management Group LLC now owns 1,562 shares of the company’s stock worth $351,000 after acquiring an additional 298 shares during the period. Pensionfund Sabic boosted its holdings in Cencora by 38.5% in the fourth quarter. Pensionfund Sabic now owns 7,200 shares of the company’s stock valued at $1,618,000 after purchasing an additional 2,000 shares during the period. Nordea Investment Management AB grew its stake in Cencora by 40.2% during the 4th quarter. Nordea Investment Management AB now owns 1,077,272 shares of the company’s stock worth $243,173,000 after purchasing an additional 308,773 shares in the last quarter. Finally, Modus Advisors LLC purchased a new stake in Cencora during the 4th quarter worth about $54,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This represents a 7.62 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Steven H. Collis sold 50,000 shares of Cencora stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $243.97, for a total value of $12,198,500.00. Following the completion of the transaction, the chairman now owns 326,557 shares in the company, valued at $79,670,111.29. This trade represents a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 94,696 shares of company stock worth $22,862,734. 15.80% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on COR. StockNews.com downgraded Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Mizuho assumed coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective for the company. Robert W. Baird increased their target price on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Barclays lifted their price target on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Finally, UBS Group increased their price objective on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $275.60.

Cencora Stock Performance

NYSE COR traded down $0.45 on Monday, reaching $228.75. The stock had a trading volume of 446,821 shares, compared to its average volume of 961,174. The stock has a market cap of $44.21 billion, a P/E ratio of 30.46, a price-to-earnings-growth ratio of 1.54 and a beta of 0.45. Cencora, Inc. has a 12-month low of $208.58 and a 12-month high of $253.27. The business’s 50-day moving average price is $237.44 and its 200 day moving average price is $233.60. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were given a dividend of $0.55 per share. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a yield of 0.96%. The ex-dividend date of this dividend was Friday, November 15th. Cencora’s dividend payout ratio (DPR) is presently 29.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.